Dominican RepublicTuberculosis profile
Population  2016 11 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.56 (0.24–1) 5.2 (2.3–9.5)
Mortality (HIV+TB only) 0.49 (0.35–0.64) 4.6 (3.3–6)
Incidence  (includes HIV+TB) 6.4 (4.9–8.2) 60 (46–77)
Incidence (HIV+TB only) 1.5 (1.1–2) 14 (11–19)
Incidence (MDR/RR-TB)** 0.42 (0.3–0.55) 4 (2.9–5.1)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.37 (0.27–0.46) 2 (1.5–2.6) 2.4 (1.8–3)
Males 0.38 (0.28–0.48) 3.7 (2.7–4.6) 4 (3–5.1)
Total 0.75 (0.55–0.94) 5.7 (4.2–7.2) 6.4 (4.9–8.2)
TB case notifications, 2016  
Total cases notified 4 476
Total new and relapse 4 235
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 88%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 63%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 66% (52–87)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.1–0.25)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 893 24%
          - on antiretroviral therapy 376 42%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  290
(230–360)
Estimated % of TB cases with MDR/RR-TB 2.9% (1.4–4.5) 34% (28–41)  
% notified tested for rifampicin resistance 7% 36% 527
MDR/RR-TB cases tested for resistance to second-line drugs   98
Laboratory-confirmed cases MDR/RR-TB: 107, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 140, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 80% 4 468
Previously treated cases, excluding relapse, registered in 2015 63% 201
HIV-positive TB cases registered in 2015 65% 909
MDR/RR-TB cases started on second-line treatment in 2014 50% 100
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 20%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 15
Funding source: 65% domestic, 19% international, 17% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data